Ranbaxy Laboratories rises on getting AA+ rating for its proposed NCD from CARE

31 Aug 2012 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 551.60, up by 2.25 points or 0.41% from its previous closing of Rs. 549.35 on the BSE.

The scrip opened at Rs. 546.25 and has touched a high and low of Rs. 554.00 and Rs. 546.00 respectively. So far 44476 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 562.00 on 27-Aug-2012 and a 52 week low of Rs. 366.50 on 19-Dec-2011.

Last one week high and low of the scrip stood at Rs. 562.00 and Rs. 544.25 respectively. The current market cap of the company is Rs. 23243.57 crore.

The promoters holding in the company stood at 63.66% while Institutions and Non-Institutions held 20.74% and 13.61% respectively.

Credit rating agency, CARE has assigned AA+ rating to Ranbaxy Laboratories’ long-term proposed Non Convertible Debentures (NCD) worth Rs 500 crore.

The company has received the said rating on the back of its dominant position in the domestic pharmaceutical market coupled with its established presence in the global market, which is further expected to strengthen, given its strong pipeline of Abbreviated New Drug Applications (ANDA), including First-to-file (FTF) applications.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×